Insight Molecular Diagnostics (IMDX) Total Non-Current Liabilities (2019 - 2026)

Insight Molecular Diagnostics has reported Total Non-Current Liabilities for 8 years, with the latest figure at $13.3 million in Q1 2026.

• Quarterly Total Non-Current Liabilities fell 4.56% year-over-year to $13.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $13.3 million (down 4.56% YoY) and the FY2025 annual result came in at $13.8 million, up 14.62% from the prior year.
• Total Non-Current Liabilities slipped to $13.3 million in Q1 2026 per IMDX's latest filing, from $13.8 million in the prior quarter.
• Over five years, Total Non-Current Liabilities peaked at $81.9 million in Q1 2022 and troughed at $8.5 million in Q2 2025.
• A 5-year average of $31.8 million and a median of $13.9 million in 2025 frame the typical range for Total Non-Current Liabilities.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities surged 464.85% in 2022, then plunged 83.45% in 2023.
• Over 5 years, Total Non-Current Liabilities stood at $55.1 million in 2022, then slumped by 83.45% to $9.1 million in 2023, then soared by 31.62% to $12.0 million in 2024, then increased by 14.62% to $13.8 million in 2025, then decreased by 3.29% to $13.3 million in 2026.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $13.3 million, $13.8 million, and $9.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.